| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Magdalena Grill, Carina Hasenoehrl, Martin Storr, Rudolf Schich. Medical Cannabis and Cannabinoids: An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon? Medical cannabis and cannabinoids. vol 1. issue 1. 2021-10-23. PMID:34676319. |
medical cannabis and cannabinoids: an option for the treatment of inflammatory bowel disease and cancer of the colon? |
2021-10-23 |
2023-08-13 |
human |
| Jürg Gertsc. The Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids. Medical cannabis and cannabinoids. vol 1. issue 1. 2021-10-23. PMID:34676323. |
the intricate influence of the placebo effect on medical cannabis and cannabinoids. |
2021-10-23 |
2023-08-13 |
Not clear |
| Joseph V Pergolizzi, Jo Ann LeQuang, John F Bisne. Cannabinoid Hyperemesis. Medical cannabis and cannabinoids. vol 1. issue 2. 2021-10-23. PMID:34676325. |
cannabinoid hyperemesis syndrome (chs) is a paradoxical condition in which a long-term cannabis user suffers an episode of intractable vomiting that may last days separated by longer asymptomatic periods of weeks or months. |
2021-10-23 |
2023-08-13 |
Not clear |
| Aleksi Mikael Markunpoika Hupl. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Medical cannabis and cannabinoids. vol 1. issue 2. 2021-10-23. PMID:34676327. |
medical cannabis for adult attention deficit hyperactivity disorder: sociological patient case report of cannabinoid therapeutics in finland. |
2021-10-23 |
2023-08-13 |
Not clear |
| Paul T Kocis, Kent E Vran. Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions. Medical cannabis and cannabinoids. vol 3. issue 1. 2021-10-23. PMID:34676340. |
in the case of medical cannabis and medicinal cannabinoids, this is further complicated by the fact that the increased therapeutic use of marijuana extracts and cannabidiol oil will not have regulatory agency approved pi. |
2021-10-23 |
2023-08-13 |
Not clear |
| Paul T Kocis, Kent E Vran. Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions. Medical cannabis and cannabinoids. vol 3. issue 1. 2021-10-23. PMID:34676340. |
in addition to a comprehensive list of drug-drug interactions, we also provide a list of 57 prescription medications displaying a narrow therapeutic index that are potentially impacted by concomitant cannabinoid use (whether through prescription use of cannabinoid medications or therapeutic/recreational use of cannabis and its extracts). |
2021-10-23 |
2023-08-13 |
Not clear |
| Wesley M Raup-Konsavage, Nurgul Carkaci-Salli, Kelly Greenland, Robert Gearhart, Kent E Vran. Cannabidiol (CBD) Oil Does Not Display an Entourage Effect in Reducing Cancer Cell Viability in vitro. Medical cannabis and cannabinoids. vol 3. issue 2. 2021-10-23. PMID:34676344. |
several studies have found that cannabinoids, particularly delta-9-tetrahydrocannabinol and cannabidiol (cbd), have the ability to reduce cancer cell viability. |
2021-10-23 |
2023-08-13 |
Not clear |
| Joshua D Brown, Amie J Goodi. Evidence in Context: High Risk of Bias in Medical Cannabis and Cannabinoid Clinical Trials Dictates the Need for Cautious Interpretation. Medical cannabis and cannabinoids. vol 4. issue 1. 2021-10-23. PMID:34676351. |
evidence in context: high risk of bias in medical cannabis and cannabinoid clinical trials dictates the need for cautious interpretation. |
2021-10-23 |
2023-08-13 |
Not clear |
| Robin van Velzen, M Eric Schran. Origin and Evolution of the Cannabinoid Oxidocyclase Gene Family. Genome biology and evolution. vol 13. issue 8. 2021-10-22. PMID:34100927. |
medicinal and psychoactive effects of cannabis rely on specific terpenophenolic ligands named cannabinoids. |
2021-10-22 |
2023-08-13 |
Not clear |
| Robin van Velzen, M Eric Schran. Origin and Evolution of the Cannabinoid Oxidocyclase Gene Family. Genome biology and evolution. vol 13. issue 8. 2021-10-22. PMID:34100927. |
results show that cannabinoid oxidocyclase genes originated in the cannabis lineage from within a larger gene expansion in the cannabaceae family. |
2021-10-22 |
2023-08-13 |
Not clear |
| Robin van Velzen, M Eric Schran. Origin and Evolution of the Cannabinoid Oxidocyclase Gene Family. Genome biology and evolution. vol 13. issue 8. 2021-10-22. PMID:34100927. |
localization and divergence of oxidocyclase genes in the cannabis genome revealed two main syntenic blocks, each comprising tandemly repeated cannabinoid oxidocyclase genes. |
2021-10-22 |
2023-08-13 |
Not clear |
| Robin van Velzen, M Eric Schran. Origin and Evolution of the Cannabinoid Oxidocyclase Gene Family. Genome biology and evolution. vol 13. issue 8. 2021-10-22. PMID:34100927. |
although wild populations of cannabis are still unknown, increased sampling of landraces and wild/feral populations across its native geographic range is likely to uncover additional cannabinoid oxidocyclase sequence variants. |
2021-10-22 |
2023-08-13 |
Not clear |
| Waleed Hassan Almalk. A study of abnormal cannabidiols system-mediated cardiovascular protection in disrupted gut/brain axis associated depression. Journal of biochemical and molecular toxicology. 2021-10-22. PMID:34676637. |
the cardiovascular effects of tetrahydrocannabinol (thc) (the key psychotropic credential of cannabis) and endocannabinoids (thc endogenous equivalents which cause type 1 [cb1] and 2 [cb2] cannabinoids) have been extensively examined based on well-documented effects of marijuana smoke on blood pressure (bp) and heart rate (hr). |
2021-10-22 |
2023-08-13 |
Not clear |
| Chia-Shan Wu, Christopher P Jew, Hui-Chen L. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future neurology. vol 6. issue 4. 2021-10-21. PMID:22229018. |
lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. |
2021-10-21 |
2023-08-12 |
human |
| Chia-Shan Wu, Christopher P Jew, Hui-Chen L. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future neurology. vol 6. issue 4. 2021-10-21. PMID:22229018. |
in this article, we examine human longitudinal cohort studies that document the long-term influence of prenatal exposure to cannabis, followed by an overview of the molecular composition of the endocannabinoid system and the temporal and spatial changes in their expression during brain development. |
2021-10-21 |
2023-08-12 |
human |
| Carmen Lorena Robaina Cabrera, Sandra Keir-Rudman, Nick Horniman, Nick Clarkson, Clive Pag. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary pharmacology & therapeutics. vol 69. 2021-10-21. PMID:34082108. |
studies with cannabis sativa plant extracts and endogenous agonists of cannabinoid receptors have demonstrated anti-inflammatory, bronchodilator, and antitussive properties in the airways of allergic and non-allergic animals. |
2021-10-21 |
2023-08-13 |
Not clear |
| Carmen Lorena Robaina Cabrera, Sandra Keir-Rudman, Nick Horniman, Nick Clarkson, Clive Pag. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary pharmacology & therapeutics. vol 69. 2021-10-21. PMID:34082108. |
however, the potential therapeutic use of cannabis and cannabinoids for the treatment of respiratory diseases has not been widely investigated, in part because of local irritation of airways by needing to smoke the cannabis, poor bioavailability when administered orally due to the lipophilic nature of cannabinoids, and the psychoactive effects of Δ9-tetrahydrocannabinol (Δ9-thc) found in cannabis. |
2021-10-21 |
2023-08-13 |
Not clear |
| Carmen Lorena Robaina Cabrera, Sandra Keir-Rudman, Nick Horniman, Nick Clarkson, Clive Pag. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary pharmacology & therapeutics. vol 69. 2021-10-21. PMID:34082108. |
the primary purpose of this study was to investigate the anti-inflammatory effects of two of the non-psychotropic cannabinoids, cannabidiol (cbd) and cannabigerol (cbg) alone and in combination, in a model of pulmonary inflammation induced by bacterial lipopolysaccharide (lps). |
2021-10-21 |
2023-08-13 |
Not clear |
| Gi Liou, Ab El-Remessy, As Ibrahim, Rb Caldwell, Ym Khalifa, A Gunes, Jj Nussbau. Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development. Current pharmacogenomics and personalized medicine. vol 7. issue 3. 2021-10-20. PMID:20953236. |
this review is focused on cannabidiol, a non-psychoactive native cannabinoid, as an emerging and novel therapeutic modality based on systematic studies in animal models of inflammatory retinal diseases including diabetic retinopathy - one of the retinal diseases associated with vascular neuroinflammation. |
2021-10-20 |
2023-08-12 |
Not clear |
| Philip R Cohe. Therapeutic and Cosmetic Uses of Cannabis: Cannabinoids for Acne Treatment and Skin -Rejuvenation. Skinmed. vol 19. issue 1. 2021-10-19. PMID:33658112. |
therapeutic and cosmetic uses of cannabis: cannabinoids for acne treatment and skin -rejuvenation. |
2021-10-19 |
2023-08-13 |
Not clear |